Robert McKallip, PhD

McKallip, RobEducation

  • BS, Biology, Virginia Tech
  • MS, Immunology, Virginia Tech
  • PhD, Molecular and Cellular Oncology, The George Washington University
  • Postdoctoral Study, Tumor Immunology, Virginia Tech
  • Postdoctoral Study, Tumor Immunology, Medical College of Virginia

Research Interest

Dr. McKallip’s laboratory primary focus is on determining the role of CD44 in the regulation of the immune response. Specific projects include; exploring novel strategies to stimulate the immune response to tumors, understanding mechanisms used by tumor cells to escape immune recognition , and destruction as well as exploring the possibility of targeting CD44 isoform expression for the treatment of complication associated with MRSA infections.

Selected Publications

  • Bentz GL, Lowrey AJ, Horne DC, Nguyen V, Satterfield AR, Ross TD, Harrod AE, Uchakina ON, McKallip RJ. Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency. PLoS One. 2019 May 24;14(5). PMID: 31125383
  • Orr SE, Barnes MC, Joshee L, Uchakina O, McKallip RJ, Bridges CC. Potential mechanisms of cellular injury following exposure to a physiologically relevant species of inorganic mercury. Toxicol Lett. 2019 Apr;304:13-20. doi: 10.1016/j. PMID: 30630035
  • Yang LW, Qin DZ, James E, McKallip RJ, Wang NP, Zhang WW, Zheng RH, Han QH, Zhao ZQ. CD44 Deficiency in Mice Protects the Heart Against Angiotensin II-Induced Cardiac Fibrosis. Shock. 2019 Mar;51(3):372-380. PMID: 29470359
  • Hostetler BJ, Uchakina ON, Ban H, McKallip RJ#. Treatment of Hematological Malignancies with Glycyrrhizic Acid. Anticancer Res. 2017 Mar;37(3):997-1004. (#Corresponding Author). PMID: 28314257
  • Uchakina ON, Ban H, Hostetler BJ, McKallip RJ#. Inhibition of hyaluronic acid formation sensitizes chronic myelogenous leukemia to treatment with doxorubicin. Glycobiology. 2016 Nov;26(11):1171-1179. (#Corresponding Author). PMID 27261196
  • Bai F, Pang XF, Zhang LH, Wang NP, McKallip RJ, Garner RE, Zhao ZQ. Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44-hyaluronan interaction in rats with hypertension and myocardial fibrosis. Life Sci. 2016 May 15;153:141-52. PMID:27085217
  • Pang XF, Zhang LH, Bai F, Wang NP, Garner RE, McKallip RJ, Zhao ZQ. Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug Des Devel Ther. 2015 Nov 11;9:6043-54. PMID: 26648693
  • Ban H, Uchakina O, McKallip RJ#. Hyaluronic Acid Inhibitor 4-Methylumbelliferone Activates the Intrinsic Apoptosis Pathway in K562 Chronic Myelogenous Leukemia Cells. Anticancer Res. 2015 Oct;35(10):5231-40. (#Corresponding Author). PMID:26408682
  • Zhang L.H., Pang X.F., Bai F, Wang N.P., Shah A.I., McKallip R.J., Li X.W., Wang X, Zhao Z.Q.Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT 2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart. Cardiovasc Drugs Ther. 2015 May 21. [Epub ahead of print]. PMID:25994830
  • McKallip R.J#., Ban H, Uchakina O.N. Treatment with the hyaluronic Acid synthesis inhibitor 4-methylumbelliferone suppresses LPS-induced lung inflammation. Inflammation. 2015 Jun;38(3):1250-9. (#Corresponding Author). PMID:25537799


  • Immunotherapy of malignant melanoma: Role of CD44 isoforms. Georgia Cancer Coalition Cancer Research Award. McKallip (PI) 04/01/2010-09/30/2011. $50,000.
  • The role of CD44 isoforms in immunotherapy of melanoma. NCI/NIH (K22-CA109334). McKallip (PI) 08/01/2006-05/30/2007. $152,927.
  • The role of CD44 isoforms in immunotherapy of melanoma. Commonwealth Health Research Fund. McKallip (PI) 2005-2006. $85,770.
  • The role of CD44 isoforms in immunotherapy of melanoma. A.D. Williams Fund: McKallip (PI) 2005. $15,000.
  • The effects of cannabinoid exposure on tumor growth and the anti-tumor immune response. Jeffress Memorial Trust, McKallip (PI) 2004-2005. $30,000.
  • The effects of cannabinoid exposure on tumor growth and the anti-tumor immune response. NIDA Small Grants Program Subaward, McKallip (PI) 2003-2004.$13,000.
  • Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Scholar. NIH/NIDA K12 DA14041.McKallip (Scholar). Provided salary support (75%) and funds for supplies and travel.
  • Targeting cannabinoid receptors as a novel treatment of breast cancer”. American Cancer Society (IRG-100036) Subaward, McKallip (PI) 2003-2004, $15,000.
  • The role of CD44 isoforms in endothelial cell damage. Individual National Research Service Award (NIH) F32 HL10455. McKallip (PI) 08/01/2000-11/10/2002, $79,789, PI: Robert McKallip.

Professional Involvement

  • American Association for Cancer Research
  • American Association of Immunologists


Contact Dr. Robert McKallip